Threshold Pharmaceuticals
Threshold Pharmaceuticals Newswire

Threshold Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Threshold Pharmaceuticals.

Results 1 - 20 of 58 in Threshold Pharmaceuticals

  1. Threshold Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial Of...Read the original story

    Wednesday Aug 26 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" , for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin . Tarloxotinib is Threshold's proprietary, hypoxia-activated, irreversible epidermal growth factor receptor tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand.

    Comment?

  2. Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of...Read the original story

    Thursday Aug 27 | Freshnews

    Threshold Pharmaceuticals, Inc. today announced that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" , for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin . Tarloxotinib is Threshold's proprietary, hypoxia-activated, irreversible epidermal growth factor receptor tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand.

    Comment?

  3. Threshold Pharmaceuticals, Inc. And Initiate First Phase 2 Clinical...Read the original story

    Monday Aug 10 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium , has initiated the first Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" , for the treatment of patients with mutant epidermal growth factor receptor non-small cell lung cancer who have been previously treated with an EGFR tyrosine kinase inhibitor and are progressing on treatment, but have not acquired the T790M resistance mutation. Tarloxotinib is Threshold's proprietary, hypoxia-activated, irreversible EGFR tyrosine kinase inhibitor licensed from the University of Auckland, New Zealand.

    Comment?

  4. Threshold Pharmaceuticals Rating Reiterated by Piper JaffrayRead the original story

    Tuesday Aug 11 | AmericanBankingNews.com

    ... company. Cantor Fitzgerald reaffirmed a "buy" rating and issued a $14.00 price target on shares of Threshold Pharmaceuticals in a report on Thursday, July 30th. MLV & Co. set a $14.50 price target on Threshold Pharmaceuticals and gave the company a ...

    Comment?

  5. Threshold Pharmaceuticals and ATOMIC Initiate First Phase 2 Clinical...Read the original story

    Tuesday Aug 11 | Freshnews

    08/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), has initiated the first Phase 2 clinical trial of ...

    Comment?

  6. Threshold Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial And Operational ResultsRead the original story

    Aug 2, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today reported financial results for the second quarter 2015. Revenue for the second quarter ended June 30, 2015 was $3.7 million.

    Comment?

  7. Threshold Pharmaceuticals Reports Second Quarter 2015 Financial and Operational ResultsRead the original story

    Jul 30, 2015 | Freshnews

    07/30/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the second quarter 2015. Revenue for the second quarter ended June 30, 2015 was $3.7 million. The operating loss for the second quarter ended June 30, ...

    Comment?

  8. Threshold Pharmaceuticals: Hard Road Toward SuccessRead the original story w/Photo

    Jul 28, 2015 | Seeking Alpha

    Threshold has been unloved for the past 9 years, and many are critical of its tumor hypoxia-based platform. Market cap is under $300 million or about 21x TTM revenue.

    Comment?

  9. Soft Tissue Sarcoma Therapeutic Assessment Pipeline Review H1 2015Read the original story

    Jul 22, 2015 | Emailwire.com

    ... Shionogi & Co., Ltd., Siena Biotech S.p.A., Sigma-Tau S.p.A., Sumitomo Dainippon Pharma Co., Ltd., Threshold Pharmaceuticals, Inc., TRACON Pharmaceuticals, Inc. and Vicore Pharma AB Drugs Profile Discussed in this Research : afatinib, AL-3818, ...

    Comment?

  10. Threshold Pharmaceuticals, Inc. Announces Presentation And Webcast At The ConferenceRead the original story

    Jul 1, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Cantor Fitzgerald Healthcare Conference on July 8, 2015, at 3:45 p.m. Eastern Time. A live webcast of the presentation will be available under Webcasts in the Investors section of www.thresholdpharm.com .

    Comment?

  11. Threshold Pharmaceuticals Announces Presentation and Webcast at the...Read the original story w/Photo

    Jul 1, 2015 | Market Wire

    ... of www.thresholdpharm.com . A replay of the presentation will be archived on the site for 30 days. Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen ...

    Comment?

  12. Threshold Pharmaceuticals Given a $14.50 Price Target by MLV & Co. AnalystsRead the original story

    Jun 4, 2015 | AmericanBankingNews.com

    ... target price indicates a potential upside of 289.78% from the company's current price. Shares of Threshold Pharmaceuticals ( NASDAQ:THLD ) traded down 3.63% during mid-day trading on Thursday, hitting $3.72. The stock had a trading volume of 365,200 ...

    Comment?

  13. ASCO15: Threshold Pharmaceuticals, Inc. Presents Encouraging...Read the original story

    May 31, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced new preliminary data from the Phase 2 component of an ongoing Phase 1/2 trial of evofosfamide in combination with the proteasome inhibitor Velcade and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. A clinical benefit rate of 29% was observed in patients treated at the recommended Phase 2 dose of evofosfamide ) in EBorD.

    Comment?

  14. Threshold Pharmaceuticals Presents Encouraging Preliminary Phase 2 Data in Multiple Myeloma at ASCORead the original story

    May 31, 2015 | Freshnews

    05/31/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Phase 1/2 trial of evofosfamide (an investigational compound formerly known as TH-302) in combination with the ...

    Comment?

  15. EMD Serono Continues Its Entry Into Oncology With The Key...Read the original story w/Photo

    May 27, 2015 | BioSpace

    ... also advance Pfizer's anti-PD-1 antibody. This month, the company also announced with its partner Threshold Pharmaceuticals that the U.S. Food and Drug Administration has granted Fast Track designation for the development of its investigational ...

    Comment?

  16. Threshold Pharmaceuticals Announces Presentation and Webcast at the...Read the original story

    May 27, 2015 | Freshnews

    05/27/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies 2015 Healthcare Conference on June 3, 2015, at 4:00 p.m. ...

    Comment?

  17. Merck KGaA, Darmstadt, Germany to Present Data at ASCO That...Read the original story

    May 15, 2015 | Canada NewsWire

    ... for evofosfamide in multiple myeloma and melanoma. Evofosfamide is being co-developed with Threshold Pharmaceuticals, Inc. and is currently in Phase III studies for the treatment of soft tissue sarcoma and for pancreatic cancer, as well as in a ...

    Comment?

  18. Merck KGaA, Threshold win fast track for pancreatic cancer drugRead the original story

    May 12, 2015 | WNFL-AM Green Bay

    Germany's Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration. The drug attacks body tissue that is short of oxygen supply, a typical characteristic of many tumors because cancerous cells often grow without connecting to the blood vessels around them.

    Comment?

  19. Tuesday Pre-Market Insights: THLD, PLL, AOL, CALLRead the original story w/Photo

    May 12, 2015 | GuruFocus.com

    Threshold Pharmaceuticals, Inc. increased more than 26% in pre-market trading to $4.76 after the pharmaceutical company announced that TH-302 received FDA fast-track designation. The pancreatic cancer drug is being produced in partnership with Merck.

    Comment?

  20. Threshold Pharmaceuticals, Inc.' Partner Merck KGaA, Darmstadt,...Read the original story

    May 11, 2015 | BioSpace

    Threshold Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide , administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. This is the second Fast Track designation for evofosfamide, the first having been granted to Threshold in November 2014 for the development of evofosfamide in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma.

    Comment?